Myeloperoxidase as a Potential Biomarker of Acute-Myocardial-Infarction-Induced Depression and Suppression of the Innate Immune System

Abstract

While myeloperoxidase (MPO) serves as an indicator of both neutrophil and innate-immune-system function, the potential suppression of the innate immune system in patients with acute myocardial infarction (AMI)-induced depression might be evidenced by a decrease in MPO serum levels. The aim of this prospective study was to (1) determine whether serum concentrations of MPO vary immediately and 6 months after AMI and (2) to investigate whether MPO concentrations at the time of the AMI are significant predictors of AMI-induced depression and the depression-associated suppression of the innate immune system. A total of 109 AMI patients were assessed with the Hamilton Depression Scale (HAMD-17) immediately after admission to the hospital and 6 months later. The MPO status was assessed with serum samples, which were also collected immediately and 6 months after AMI. The depressive patients showed significantly lower MPO blood levels immediately and 6 months after the AMI compared to the patients without depression (ANCOVA: MPO (depression) F = 4.764, df = 1, p = 0.031). The baseline MPO was observed as a significant predictor (p = 0.027) of AMI-induced depression 6 months after AMI. MPO is a potential biomarker for AMI-induced depression, indicating a depression-associated suppression of the innate immune system.

Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis

“…Research reported that increased level of SHMT2 [625] and MPO (myeloperoxidase) [640] are related to pulmonary hypertension, as a novel target for pulmonary hypertension diagnosis and treatment. A recent study found that the S100A9 [239], FKBP5 [240], SNCA (synuclein alpha) [221] and MPO (myeloperoxidase) [256] are crucial for the progression of depression and anxiety. Regulation of MPO (myeloperoxidase) [1445] and CD177 [1440] levels might be a novel treatment option against polycythemia.…”

Linking Enlarged Choroid Plexus with Plasma Analyte and Structural Phenotypes in Clinical High Risk for Psychosis: A Multisite Neuroimaging Study

“…Elevated serum MPO has been described in multiple sclerosis 49 , depression 50 , and schizophrenia 51 . Interestingly, Baranyi et al (2022) 52 described lower MPO levels in patients with acute myocardial infarction (AMI) induced depression compared to AMI patients that did not develop depression. This suggests that there may be an interaction occurring between inflammatory and neuropsychiatric states with regards to MPO serum levels, but further research is needed.…”